These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12954180)

  • 21. Gelatin coated hybrid lipid nanoparticles for oral delivery of amphotericin B.
    Jain S; Valvi PU; Swarnakar NK; Thanki K
    Mol Pharm; 2012 Sep; 9(9):2542-53. PubMed ID: 22845020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid.
    Joly V; Farinotti R; Saint-Julien L; Chéron M; Carbon C; Yeni P
    Antimicrob Agents Chemother; 1994 Feb; 38(2):177-83. PubMed ID: 8192439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses.
    Brajtburg J; Elberg S; Kobayashi GS; Bolard J
    Antimicrob Agents Chemother; 1994 Feb; 38(2):300-6. PubMed ID: 8192456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimization of the hydrophobic domain in poly(ethylene oxide)-poly(varepsilon-caprolactone) based nano-carriers for the solubilization and delivery of Amphotericin B.
    Falamarzian A; Lavasanifar A
    Colloids Surf B Biointerfaces; 2010 Nov; 81(1):313-20. PubMed ID: 20674292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy evaluation of a novel submicron amphotericin B emulsion in murine candidiasis.
    Levy MY; Polacheck I; Barenholz Y; Benita S
    J Med Vet Mycol; 1993; 31(3):207-18. PubMed ID: 8360812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reformulation of Fungizone by PEG-DSPE Micelles: Deaggregation and Detoxification of Amphotericin B.
    Alvarez C; Shin DH; Kwon GS
    Pharm Res; 2016 Sep; 33(9):2098-106. PubMed ID: 27198671
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.
    Jung SH; Lim DH; Jung SH; Lee JE; Jeong KS; Seong H; Shin BC
    Eur J Pharm Sci; 2009 Jun; 37(3-4):313-20. PubMed ID: 19491021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the aggregation state of amphotericin B on its toxicity to mice.
    Barwicz J; Christian S; Gruda I
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2310-5. PubMed ID: 1444311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced renal toxicity of nanoparticular amphotericin B micelles prepared with partially benzylated poly-L-aspartic acid.
    Yoo BK; Jalil Miah MA; Lee ES; Han K
    Biol Pharm Bull; 2006 Aug; 29(8):1700-5. PubMed ID: 16880628
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nephrotoxicity of amphotericin B is attenuated by solubilizing with lipid emulsion.
    Dórea EL; Yu L; De Castro I; Campos SB; Ori M; Vaccari EM; Lacaz Cda S; Seguro AC
    J Am Soc Nephrol; 1997 Sep; 8(9):1415-22. PubMed ID: 9294833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicity of an effective amphotericin B formulation at high cationic lipid to drug molar ratio.
    Lincopan N; Borelli P; Fock R; Mamizuka EM; Carmona-Ribeiro AM
    Exp Toxicol Pathol; 2006 Nov; 58(2-3):175-83. PubMed ID: 16982179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation.
    Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ
    J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
    Zhang Z; Diener RM; Lipman JM
    Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systems.
    Barwicz J; Gareau R; Audet A; Morisset A; Villiard J; Gruda I
    Biochem Biophys Res Commun; 1991 Dec; 181(2):722-8. PubMed ID: 1755853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low nephrotoxicity of an effective amphotericin B formulation with cationic bilayer fragments.
    Lincopan N; Mamizuka EM; Carmona-Ribeiro AM
    J Antimicrob Chemother; 2005 May; 55(5):727-34. PubMed ID: 15761070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats.
    Risovic V; Boyd M; Choo E; Wasan KM
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3339-42. PubMed ID: 14506053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating.
    Petit C; Chéron M; Joly V; Rodrigues JM; Bolard J; Gaboriau F
    J Antimicrob Chemother; 1998 Dec; 42(6):779-85. PubMed ID: 10052902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index.
    Zia Q; Azhar A; Kamal MA; Aliev G; Owais M; Ashraf GM
    Curr Pharm Des; 2016; 22(7):792-803. PubMed ID: 26648472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biodegradable functional polycarbonate micelles for controlled release of amphotericin B.
    Wang Y; Ke X; Voo ZX; Yap SSL; Yang C; Gao S; Liu S; Venkataraman S; Obuobi SAO; Khara JS; Yang YY; Ee PLR
    Acta Biomater; 2016 Dec; 46():211-220. PubMed ID: 27686042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and toxicity evaluation of new amphotericin B micelle systems for brain fungal infections.
    Moreno-Rodríguez AC; Torrado-Durán S; Molero G; García-Rodríguez JJ; Torrado-Santiago S
    Int J Pharm; 2015 Oct; 494(1):17-22. PubMed ID: 26256151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.